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The success of hematopoietic stem cell transplantation (HSCT) with reduced-intensity conditioning (RIC) is
limited by a high rate of disease relapse. Early risk assessment could potentially improve outcomes by
identifying appropriate patients for preemptive strategies that may ameliorate this high risk. Using a series of
landmark analyses, we investigated the predictive value of early (day-30) donor chimerism measurements on
disease relapse, graft-versus-host disease, and survival in a cohort of 121 patients allografted with a uniform
RIC regimen. Chimerism levels were analyzed as continuous variables. In multivariate analysis, day-30 whole
blood chimerism levels were signiﬁcantly associated with relapse (hazard ratio [HR] ¼ .90, P < .001), relapse-
free survival (HR ¼ .89, P < .001), and overall survival (HR ¼ .94, P ¼ .01). Day-30 T cell chimerism levels were
also signiﬁcantly associated with relapse (HR ¼ .97, P ¼ .002), relapse-free survival (HR ¼ .97, P < .001), and
overall survival (HR ¼ .99, P ¼ .05). Multivariate models that included T cell chimerism provided a better
prediction for these outcomes compared with whole blood chimerism. Day-30 chimerism levels were not
associated with acute or chronic graft-versus-host disease. We found that high donor chimerism levels were
signiﬁcantly associated with a low lymphocyte count in the recipient before transplant, highlighting the
impact of pretransplant lymphopenia on the kinetics of engraftment after RIC HSCT. In summary, low donor
chimerism levels are associated with relapse and mortality and can potentially be used as an early predictive
and prognostic marker. These ﬁndings can be used to design novel approaches to prevent relapse and to
improve survival after RIC HSCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Reduced-intensity conditioning (RIC) regimens are asso-
ciated with decreased treatment-related mortality and make
allogeneic hematopoietic stem cell transplantation (HSCT)
feasible in older patients and those with comorbidities. The
primary barrier to the success of RIC HSCT is disease relapse
[1]. The risk of relapse after RIC is 25% to 60% [2-7], and the
median time to disease relapse is 3 to 7 months [8-11],
implying that identiﬁcation of patients at high risk for
relapse should be done very early, optimally within the ﬁrst
fewweeks after transplant. The ability to detect relapse earlyedgments on page 1765.
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14.07.003in the post-transplant period is fundamental to the design of
interventions that can potentially prevent disease recurrence
and improve survival, such as maintenance regimens or
preemptive donor lymphocyte infusions (DLIs).
The level of donorerecipient chimerism is an established
method to document donor engraftment [12] and can be
conducted in whole blood (WB) and bone marrow and in
cellular subsets such as T cells, myeloid cells, and CD34þ cells
[13,14]. The kinetics of donor chimerism after myeloablative
transplants have been characterized, but associations be-
tween attainment of complete donor chimerism and disease
relapse or survival have not been consistently demonstrated
[15-18].
In contrast to myeloablative transplants, RIC HSCT
frequently results in varying degrees of mixed chimerism
that may persist for months [19,20], but the underlying
biological features that determine this heterogeneity amongTransplantation.
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studies of RIC HSCT have shown conﬂicting results regarding
the correlation between early chimerism levels and disease
relapse [19-22]. As a result, interpreting chimerism mea-
surements in this setting remains uncertain, therefore
limiting their clinical utility.
Our goal was to examine the utility of early chimerism
measurement for prediction of disease relapse, graft-versus-
host disease (GVHD), and survival. We therefore used a
landmark analysis to investigate the predictive power of day-
30WBandTcell chimerism levels for subsequentoutcomes of
patients undergoing RIC HSCTwith a uniform and commonly
used conditioning regimen.
METHODS
Patients and Treatment
We reviewed data on adult recipients of a ﬁrst allogeneic peripheral
blood HSCTwhowere allograftedwith a uniform RIC regimen (ﬂudarabineþ
busulfan) for a malignant hematological disorder between August 2006 and
April 2013 at the University of Pennsylvania.We excluded patients whowere
transplanted for primary myeloﬁbrosis where it is difﬁcult to accurately
deﬁne relapse and patients who did not have available results of day-30
chimerism levels. Because graft rejection was rare in this cohort (n ¼ 3),
we excluded these patients. Our study population included 121 patients. To
account for the heterogeneity of the cohort in disease type and disease
burden, we reviewed relevant disease characteristics (ie, cytogenetics in
acute myeloid leukemia and myelodysplastic syndrome, disease subtype in
myelodysplastic syndrome, disease stage and status in all diseases) and
calculated the Disease Risk Index (DRI), a stratiﬁcation system that predicts
overall survival (OS) based on disease parameters. We used the 3-group
version of the DRI that was recently validated using a large dataset from
the Center for International Blood and Marrow Transplant Research [23].
Additional variables collected were the Karnofsky performance status and
the hematopoietic cell transplantationespeciﬁc comorbidity index [24]. The
Institutional Review Board of the University of Pennsylvania approved the
study. All participants provided written informed consent for data collection
at the time of their transplant.
All participants received a uniform conditioning regimen of ﬂudarabine
i.v. 120 mg/m2 and busulfan i.v. 6.4 mg/kg, followed by the infusion of
granulocyte colony-stimulating factoremobilized peripheral blood stem
cells from either a related or an unrelated donor. T cell depletion was not
used. Participants received standard GVHD prophylaxis with oral tacrolimus
.06 mg/kg/d or cyclosporine 5 mg/kg/d in 2 divided doses starting on day3
and intravenous methotrexate 15 mg/m2 on day 1 and 10 mg/m2 on days 3,
6, and 11. Tacrolimus and cyclosporine doses were adjusted to attain trough
levels between 5 and 15 ng/mL and 200 and 400 ng/mL, respectively. Some
patients (n ¼ 29) received maraviroc, a CCR5 antagonist, as part of a clinical
trial in GVHD prophylaxis at doses of 150 or 300 mg twice daily between
day 2 and day þ30 [25]. All participants received standard antimicrobial
prophylaxis. Patients did not receive prophylactic DLIs.
Donorerecipient chimerism levels were measured in the peripheral
blood on day 30 using short tandem repeat analysis [26,27]. Chimerism
levels were measured in WB samples and in the T cell subset after immu-
nomagnetic positive selection of CD3þ cells (StemCell Technologies, Van-
couver, Canada). The graft composition, including the nucleated cell dose
and the CD34þ, CD3þ, CD4þ, and CD8þ cell doses, were determined using
standard procedures [28]. Absolute lymphocyte counts (ALCs) were
measured on routine complete blood counts on day 6 before starting the
conditioning regimen and again on day 0, before the stem cell infusion.
Clinical Outcomes
The clinical outcomes of interest were time to disease relapse, grades II
to IV acute GVHD, moderate to severe chronic GVHD, relapse-free survival
(RFS), and OS. Disease relapse was deﬁned as morphological, cytogenetic, or
radiological evidence of disease demonstrating pretransplant characteris-
tics. Bone marrow biopsies and appropriate imaging studies were routinely
performed at day 100 or earlier in patients with signs indicating early
relapse. The Consensus Conference criteria and National Institutes of Health
criteria were used for acute and chronic GVHD grading, respectively [29,30].
Statistical Analysis
Descriptive statistics were used to characterize distributions of variables.
Linear correlations between WB and T cell donor chimerism at day 30 and
other continuous variables were assessed by Pearson’s correlation coefﬁ-
cient, and differences between groups deﬁned by categorical variables wereassessed byeitherWilcoxon rank sumor Kruskal-Wallis tests. No adjustment
formultiple testingwas performed in the analysis of predictors of chimerism
levels. A landmark approach was used for time-to-event outcomes by
measuring the time from chimerism measurement (approximately day 30)
to the event, which allowed us to evaluate day-30 WB and T cell donor
chimerism as predictors. Time to relapse was deﬁned as the time from day-
30 chimerism measurement to ﬁrst documented relapse or last patient
contact without relapse. Other outcomes were similarly deﬁned. Patients
were censored at the time of a second transplant in all analyses and at the
time of DLI for GVHD analyses.
Competing risks regression analyses were conducted to identify pre-
dictors of time to relapse and time to GVHD outcomes, allowing for death
without the event as a competing risk. Cox regression was used to identify
predictors of survival and RFS. Univariate and multivariate analyses were
performed to identify signiﬁcant independent predictors and the primary
variables of interest, day-30 WB and T cell chimerism, were entered into all
models separately. The GVHD prophylaxis regimen was entered as a ﬁxed
covariate in the models for adjustment only because patients were not
randomized to these treatments. Additional variables considered for model
building exhibited univariate signiﬁcance of P  .10, and a step-wise elimi-
nation method was then used.
Statistical signiﬁcance of predictors in the models was assessed by the
Wald test. The Akaike Information Criterion (AIC) was used to assess the
relative goodness of ﬁt of the models built for WB and T cell chimerism.
Analyses were conducted in STATA v13.1 (STATA Corp, College Station, TX)
and R using the cmprsk package (The R Project for Statistical Computing,
http://www.rproject.org).RESULTS
Patient and transplant characteristics are summarized in
Table 1. The median follow-up was 22.5 months (range, 1.4 to
57.9 months). The median day-30 WB chimerism level was
96% (range, 77% to 100%). T cell chimerism levels were
available in 103 of 121 patients; the median day-30 T cell
chimerism was 65% (range, 18% to 100%).Predictors of Day-30 Chimerism Levels
Our goal was to assess the associations between day-30
chimerism levels and RIC HSCT outcomes. We ﬁrst exam-
ined whether day-30 chimerism levels were associated with
various patient, disease, and transplant characteristics
(Table 2).
The primary variable associated with day-30 chimerism
levels was the recipient’s ALC before transplant. Low ALC,
both preconditioning (day 6) and on day 0, was strongly
associated with higher levels of WB and T cell chimerism
levels (Figure 1, P  .0001 for all associations). The DRI
showed a signiﬁcant association with day-30 WB chimerism
and a trend (P ¼ .07) with day-30 T cell chimerism with
higher disease risk correlating with lower chimerism levels.
In addition, the total nucleated cell dose demonstrated a
positive association with WB and T cell chimerism, a slightly
higherWB chimerismwas observed in female recipients, and
higher T cell chimerism was observed in HLA-mismatched
transplants. The use of tacrolimus versus cyclosporine was
associated with lower T cell chimerism, and maraviroc did
not seem to affect chimerism levels.
We wanted to check whether the association between
pretransplant ALC and day-30 chimerism was driven pri-
marily by patients with lymphoid malignancies who are
more likely to receive lymphodepleting therapies before
transplant. Surprisingly, we found that recipients’ ALC was
associated with day-30 chimerism levels regardless of dis-
ease type (Table 3). Both preconditioning and day 0 ALCs
were highly correlated withWB and T cell chimerism in both
lymphoid and myeloid diseases (P < .005). The only associ-
ation that was strong but did not reach statistical signiﬁcance
was between preconditioning ALC and WB chimerism in
myeloid disease (P ¼ .08). These results demonstrate that
Table 2
Predictors of Day-30 Chimerism Levels
Variable WB Chimerism T Cell Chimerism
Pearson r P Pearson r P
ALC preconditioning* .34 .0001 .45 <.0001
ALC day 0* .42 <.0001 .41 <.0001
Nucleated cell dose .19 .04 .24 .01
CD34 cell dose .10 .27 .08 .42
CD3 cell dose .10 .30 .15 .13
CD4 cell dose .02 .86 .10 .35
CD8 cell dose .12 .24 .15 .14
CD4/CD8 ratio .11 .25 .17 .09
Recipient age .05 .59 .07 .47
Donor age .09 .34 .14 .17
Variable Median (range) Py Median (range) Py
Disease type .32 .23
Myeloid 96.0% (77-100%) 66.0% (18-98%)
Lymphoid 97.0% (82-100%) 82.5% (19-99%)
DRI .007z .07z
Low 98.0% (95-100%) 66.0% (59-100%)
Intermediate 96.0% (77-100%) 88.0% (18-99%)
High/very high 95.0% (82-100%) 70.0% (35-94%)
GVHD prophylaxis .30z .04z
Csa/MTX or MMF 98.0% (85-100) 87.0% (65-97%)
Tac/MTX 96.0% (82-100) 65.0% (18-100%)
Tac/MTX/MVC 97.0% (77-100) 74.5% (33-99%)
Donor source .57 .60
Sibling 96.0 (77-100%) 66.0% (18-100%)
Unrelated 96.0 (82-100%) 71.5% (19-99%)
HLA matching .99 .05
8/8 96.0% (77-100) 66.0% (18-100)
7/8 96.0% (82-100) 77.0% (47-97)
Recipient sex .56
Male 95.0% (82-100) .02 66.0% (18-99)
Female 96.0% (77-100) 70.5% (19-100)
Donor sex .33 .89
Male 96.0% (82-100) 67.5% (18-100)
Female 96.0% (77-100) 71.0% (26-99)
Recipient CMV
serostatus
.30
Positive 95.0% (82-100) 66.0% (19-100) .24
Negative 96.0% (77-100) 70.0% (18-99)
Donor CMV
serostatus
.88 .81
Positive 96.0% (83-100) 70.0% (19-99)
Negative 96.0% (77-100) 67.0% (18-100)
ABO compatibility .26 .36
No 96.0% (77-100%) 65.5% (35-99)
Yes 96.0% (82-100%) 71.0% (18-100)
CMV indicates cytomegalovirus.
Values highlighted in bold indicate P  .05.
* Natural log transformation applied.
y Wilcoxon rank sum test.
z Kruskal-Wallis test.
Table 1
Subject Characteristics (N ¼ 121)
Characteristic Value
Recipient age, median (range) 63 (21-76)
Donor age, median (range) 42 (18-73)
Recipient sex: M/F, % 60/40
Donor sex: M/F, % 55/45
Sex mismatch, % 40
Diagnosis, n (%)
Myeloid disease 84 (69)
AML 52 (43)
CR1 34 (28)
CR2 12 (10)
Not in CR 6 (5)
Favorable cytogenetics* 1 (1)
Intermediate/unknown cytogenetics* 37 (31)
Adverse cytogenetics* 14 (12)
MDS 29 (24)
Low risk* 13 (11)
High risk* 16 (13)
Intermediate/unknown cytogenetics* 17 (14)
Adverse cytogenetics* 12 (10)
CML (chronic phase 2) 3 (2)
Lymphoid disease 37 (31)
NHL 22 (18)
Indolent B-NHL 3 (2)
MCL 3 (2)
Aggressive B-NHL 3 (2)
T cell lymphoma 13 (11)
CLL 5 (4)
CR 2 (2)
PR 1 (1)
Active relapse 1 (1)
MM 3 (2)
VGPR 1 (1)
PR 2 (2)
Hodgkin lymphoma (in PR) 2 (2)
ALL (in CR1) 5 (4)
DRI, n (%)*
Low 9 (7)
Intermediate 82 (68)
High/very high 30 (25)
Donor, n (%)
Sibling 53 (44)
Unrelated 68 (56)
HLA compatibility, n (%)
8/8 match 102 (84)
Single-antigen mismatch 19 (16)
GVHD prophylaxis*, n (%)
Csa þ MTX or MMF 13 (11)
Tac þ MTX 79 (65)
Tac þ MTX þ MVC 29 (24)
Nucleated cell dose, cells/kg  108, median (range) 7.9 (1.3-19.0)
CD34þ cell dose, cells/kg  106, median (range) 5.5 (1.4-21.4)
CD3þ cell dose, cells/kg  108, median (range) 2.2 (.4-5.5)
CD4þ cell dose, cells/kg  108, median (range) 1.3 (.2-4.8)
CD8þ cell dose, cells/kg  108, median (range) .4 (.1-1.8)
AML indicates acute myelogenous leukemia; CR, complete response; MDS,
myelodysplastic syndrome; CML, chronic myeloid leukemia; NHL, non-
Hodgkin lymphoma; MCL, mantle cell lymphoma; CLL, chronic lympho-
cytic leukemia; PR, partial response; MM, multiple myeloma; ALL, acute
lymphoblastic leukemia; VGPR, very good partial response; Csa, cyclo-
sporine; MTX, methotrexate; MMF, mycophenolate mofetil; Tac, tacroli-
mus; MVC, maraviroc.
* Disease categories and DRI summarized in ref. 23.
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regardless of disease.
Relapse
Disease relapse, a major cause of mortality after RIC HSCT,
was our primary focus. The cumulative incidence of relapse
was 37.7% (95% conﬁdence interval [CI], 29.7% to 47.1%) at day
180 and 46.3% (95% CI, 37.7% to 55.9%) at 1 year. The 1-year
incidence of relapse in acute myelogenous leukemia,myelodysplastic syndrome, and non-Hodgkin lymphoma,
the most common diseases in our cohort, was 39.4%, 46.3%,
and 56.1%, respectively (P > .05 for all comparisons).
To assess the predictive power of day-30 chimerism on
relapse, we used a landmark analysis approach starting on
the day of chimerism measurement (approximately day 30).
Three patients who relapsed before the landmark date were
excluded. We ﬁrst assessed the effect of each covariate
independently of others (Table 4) and then built a multi-
variate model for prediction of time to relapse (Table 5).
Importantly, chimerism levels were analyzed as continuous
variables, and therefore the hazard ratios (HRs) reﬂect the
increased or decreased risk for the outcome for each 1%
difference in chimerism levels.
In univariate analysis, the day-30 WB chimerism level
was signiﬁcantly associated with a reduction in relapse
(HR¼ .90, 95% CI, .86 to .94; P< .001). This strong association
Figure 1. Pearson correlations between day-30 chimerism levels and preconditioning or day 0 ALCs. Donorerecipient chimerism levels were measured on day 30
post-transplant in WB (A and B; n ¼ 121) and in the CD3þ T cell fraction (C and D; n ¼ 103) of peripheral blood samples. Chimerism values are plotted against each
patient’s ALC before starting the conditioning regimen (A and C; day 6) and on the day of transplant (B and D; day 0). The x-axis intervals represent natural log
transformation. The Pearson correlation coefﬁcient (r) and P value are presented in each plot.
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crease in WB chimerism levels. Day-30 T cell chimerism
levels also demonstrated an inverse association with relapse
(HR ¼ .98, 95% CI, .97 to 1.00; P ¼ .02). Other variables
associated with relapse that met our threshold for modeling
included donor or recipient sex and the GVHD prophylaxis
regimen (cyclosporine versus tacrolimus). Because the GVHD
prophylaxis regimen was not selected by randomization, it
was treated as a confounder and used for adjustment only. In
addition, low CD8 cell doses and a high graft CD4/CD8 ratio
correlated with a higher risk for relapse.
To further characterize the association between day-30
chimerism and disease relapse and identify a chimerism
threshold that optimally predicts relapse, we examined all
possible cutoffs. WB chimerism showed a strong association
at any relevant cutoff, precluding a choice of an optimal
cutoff for prediction of relapse. For example, cutoffs of 90%,
93%, and 96% resulted in HRs of .26, .25, and .44, respectively
(all three cutoffs with P < .01). As a representative example,
cumulative incidence plots that compare disease relapse in
patients grouped according to the median WB chimerism
level (96%) are displayed in Figure 2A.We plotted the P values
for this association against all cutoff levels to demonstrate
that this association was continuous, highly signiﬁcant, and
consistent across multiple cutoff levels (Figure 2B).Table 3
Predictors of Day-30 Chimerism Levels with Pretransplant Lymphocyte
Counts in Disease Subsets
Variable WB Chimerism T Cell Chimerism
Pearson r P Pearson r P
Myeloid
ALC preconditioning* .19 .08 .34 .003
ALC day 0* .32 .004 .33 .004
Lymphoid
ALC pre-conditioning* .59 .0001 .61 .0006
ALC day 0* .59 .0001 .51 .005
Values highlighted in bold indicate P  .05.
* Natural log transformation applied.T cell chimerism levels also predicted disease relapse at
multiple cutoffs. For example, a comparison of relapse rates
in patients with day-30 T cell chimerism above and below
the median (65%) showed an HR of .56 (P ¼ .05; Figure 2C).
We assessed different cutoff levels for T cell chimerism and
found the distribution of P values was asymmetric. Cutoffs at
the median level or lower provided a better prediction than
higher cutoffs (Figure 2D). Still, we could not identify a single
optimal cutoff.
We then wanted to assess whether day-30 chimerism
levels were prognostic as opposed to diagnostic because it is
possible that patients with low chimerism levels had already
relapsed on day 30. To ascertain that the associations we
foundwere not driven by patients with very early relapse, we
repeated our analysis after excluding 6 patients who expe-
rienced relapse between days 30 and 60. We found that the
ability to predict relapse was unchanged after excluding
these early relapse patients (WB: HR ¼ .90, P < .001; T cell:
HR¼ .98, P¼ .02). This conﬁrms a window of opportunity for
intervention in most patients with low chimerism levels.
Finally, both WB and T cell chimerism levels were strong
predictors of relapse in multivariate models that were con-
structed separately for each predictor (Table 5). High DRI,
male donors, and grafts with a high CD4/CD8 cell dose ratio
remained signiﬁcant predictors for a high relapse rate. No
differential effect (ie, statistical interaction) was noted be-
tween subsets of patients with myeloid and lymphoid dis-
ease (P ¼ .66), acute leukemia and other diseases (P ¼ .58), or
unrelated and sibling donors (P ¼ .71).
RFS and OS
Because of their highly signiﬁcant correlation with
relapse, we hypothesized that day-30 chimerism levels
might predict RFS and OS. The 2-year estimated rates of RFS
and OS were 33.9% (95% CI, 25.1% to 42.9%) and 45.1% (95% CI,
35.1% to 54.6%), respectively.
We conducted a landmark analysis to determine the as-
sociations between day-30 chimerism levels and RFS or OS
Table 4
Univariate Associations with Disease Relapse, RFS and OS
Variable Univariate Associations
Relapse RFS OS
HR 95% CI P HR 95% CI P HR 95% CI P
Day 30 WB chimerism (per 1%) .90 .86-.94 <.001 .90 .86-.94 <.001 .95 .91-1.00 .04
Day 30 T cell chimerism (per 1%) .98 .97-1.00 .02 .98 .97-.99 .001 .99 .98-1.00 .09
Disease, lymphoid vs. myeloid 1.25 .72-2.19 .43 1.09 .61-1.79 .73 .75 .44-1.30 .31
DRI
Low vs. intermediate .76 .25-2.38 .64 1.00 .40-2.51 .99 1.36 .54-3.46 .52
High/very high vs. intermediate 2.56 1.44-2.53 .001 2.36 1.44-3.85 .001 2.02 1.17-3.47 .01
Donor source, URD vs. sibling .92 .54-1.57 .77 .90 .57-1.41 .63 .90 .55-1.47 .68
GVHD prophylaxis
Tac/MTX vs. Csa/MTX or MMF .38 .18-.80 .01 .30 .15-.59 .001 .42 .21-.83 .01
Tac/MTX/MVC vs. Csa/MTX or MMF .52 .23-1.16 .11 .39 .19-.83 .01 .53 .25-1.13 .10
HLA matching, 7/8 vs. 8/8 1.01 .50-2.02 .99 .98 .53-1.82 .96 1.10 .56-2.17 .78
Recipient sex, female vs. male .56 .32-.97 .04 .68 .43-1.09 .11 .60 .35-1.01 .05
Donor sex, female vs. male .63 .36-1.10 .10 1.06 .68-1.68 .79 1.59 .97-2.60 .07
Recipient age 1.02 .98-1.06 .26 1.02 .99-1.05 .31 1.02 .99-1.06 .18
Donor age 1.00 .98-1.01 .90 1.01 .99-1.02 .37 1.01 1.00-1.03 .13
CD4 dose .96 .60-1.53 .87 .98 .69-1.39 .91 .95 .66-1.36 .76
CD8 dose .44 .18-1.09 .08 .38 .18-.80 .01 .36 .16-.84 .02
CD4/CD8 dose ratio 1.14 1.04-1.24 .007 1.15 1.06-1.26 .002 1.15 1.04-1.27 .005
Nucleated cell dose .97 .89-1.06 .53 .98 .91-1.05 .52 .98 .91-1.05 .59
CD34 dose 1.04 .94-1.16 .42 1.01 .93-1.09 .84 .94 .86-1.02 .15
CD3 dose .83 .60-1.15 .26 .87 .68-1.11 .27 .85 .65-1.11 .23
ALC pre* 1.22 .85-1.73 .28 1.23 .90-1.68 .20 1.11 .80-1.54 .52
ALC day 0* 1.18 .84-1.66 .33 1.21 .91-1.60 .19 .98 .74-1.30 .90
Values highlighted in bold indicate P .05. Additional variables that lacked signiﬁcant associations and are not presented in the table include donor and recipient
cytomegalovirus serostatus, ABO compatibility, Karnofsky performance status, and hematopoietic cell transplantationespeciﬁc comorbidity index. URD denotes
unrelated donor.
* Natural log transformation applied.
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chimerism strongly correlated with RFS (HR ¼ .90, P < .001
forWB chimerism; HR¼ .98, P¼ .001 for T cell chimerism), in
addition to other factors (DRI, GVHD prophylaxis, CD8 dose,
and CD4/CD8 ratio). Multivariate models conﬁrmed the
predictive value of either WB chimerism or T cell chimerism
for RFS (Table 5).
A similar approach revealed that WB and Tcell chimerism
predicted OS in multivariate models that adjusted for the
DRI, graft CD4/CD8 ratio, and GVHD prophylaxis (HR ¼ .94,
P ¼ .01 for WB chimerism; HR ¼ .99, P ¼ .05 for T cell
chimerism). Additional variables did not improve the OS
model.
Graft-versus-Host Disease
The day-180 cumulative incidence rate of acute grade II to
IV GVHD was 40.1% (95% CI, 31.9% to 48.7%), and the 2-year
incidence rate of moderate to severe chronic GVHD was
23.8% (95% CI, 15.0% to 33.3%). We conducted a landmark
analysis to determine the associations between day-30
chimerism levels and grades II to IV acute GVHD. Eight pa-
tients who had GVHD before day 30 were excluded. In uni-
variate and multivariate analyses, day-30 WB and T cell
chimerism levels had no signiﬁcant association with time to
grades II to IV GVHD (Supplemental Table 1). We also
examined more immediate GVHD incidence rates (day 60
and day 100) and found no associations between chimerism
levels on day 30 and the occurrence of acute GVHD at these
time points (data not shown). A similar analysis for moderate
to severe chronic GVHD (Supplemental Table 2) also showed
no signiﬁcant associations. Subset analyses of GVHD out-
comes in patients who received different GVHD prophylaxis
regimens also revealed no signiﬁcant associations (data not
shown).WB versus T Cell Chimerism
All multivariate models were constructed with either WB
or T cell chimerism. Because these 2 variables were highly
correlated (Figure 3; r ¼ .61, P < .0001), models that include
both factors together arbitrarily choose 1 as signiﬁcant and
remove the other. To compare the predictive models that
included WB and T cell chimerism, we used the AIC, which
measures the relative goodness of ﬁt of a statistical model
and allows comparison between models, with the lower AIC
reﬂecting a better model. We found that the AIC was lower
(better) for T cell chimerism compared with WB chimerism
in prediction of all 3 outcomes: relapse (312 versus 365), RFS
(437 versus 504), and OS (381 versus 440), implying that
day-30 T cell chimerism may perform better in prediction of
RIC HSCT outcomes.
DISCUSSION
In this study, we found that early donorerecipient
chimerism levels, both in WB and in the T cell subset, pre-
dicted subsequent relapse in HSCT recipients who received a
peripheral blood stem cell graft after a uniform RIC regimen.
For each 1% difference in chimerism level, there was a dif-
ference of 10% (for WB chimerism) or 2% (for T cell chime-
rism) in the relative risk for subsequent relapse. Based on our
model, the projected risk for relapse at 1 year in patients who
haveWB chimerism levels of 90%, 95%, and 100% is 52%, 34%,
and 21%, respectively. Early chimerism levels also correlated
with RFS and OS but not with acute or chronic GVHD. These
associations did not differ between patients with myeloid
and lymphoid diseases or acute leukemia versus other dis-
eases. To the best of our knowledge, this study is the ﬁrst to
characterize early chimerism levels as a continuous variable
that accurately predicts relapse and survival and can be used
to identify high-risk patients after RIC HSCT. These ﬁndings
Table 5
Multivariate Models* for Disease Relapse, RFS, and OS
Multivariate Model for
WB Chimerism
Relapse
Day 30 WB chimerism (per 1%) .90 .86-.94 <.001
DRI
Low vs. intermediate 1.52 .45-5.15 .50
High/very high vs. intermediate 2.68 1.47-4.88 .001
CD4/CD8 ratio 1.20 1.10-1.31 <.001
Donor sex, female vs. male .35 .18-.69 .002
Multivariate Model for
T Cell Chimerism
Day 30 T cell chimerism (per 1%) .97 .96-.99 .002
DRI
Low vs. intermediate 1.73 .49-6.09 .39
High/very high vs. intermediate 4.30 2.30-8.02 <.001
CD4/CD8 ratio 1.18 1.08-1.29 <.001
Donor sex, female vs. male .31 .16-.61 .001
Multivariate Model for
WB Chimerism
RFS
Day 30 WB chimerism (per 1%) .89 .85-.94 <.001
DRI
Low vs. intermediate 1.66 .62-4.43 .31
High/very high vs. intermediate 2.37 1.36-4.16 .002
CD4/CD8 ratio 1.14 1.04-1.24 .006
Multivariate Model for
T Cell Chimerism
Day 30 T cell chimerism (per 1%) .97 .96-.99 <.001
DRI
Low vs. intermediate 1.60 .54-4.74 .40
High/very high vs. intermediate 3.01 1.65-5.50 <.001
CD4/CD8 ratio 1.11 1.01-1.22 .03
Multivariate Model for
WB Chimerism
OS
Day 30 WB chimerism (per 1%) .94 .89-.99 .01
DRI
Low vs. intermediate 1.78 .64-4.92 .27
High/very high vs. intermediate 1.68 .89-3.18 .11
CD4/CD8 ratio 1.14 1.04-1.26 .008
Multivariate Model for
T Cell Chimerism
Day 30 T cell chimerism (per 1%) .99 .97-1.00 .05
DRI
Low vs. intermediate 1.56 .49-4.91 .45
High/very high vs. intermediate 1.89 .95-3.72 .07
CD4/CD8 ratio 1.12 1.01-1.25 .03
Values highlighted in bold indicate P  .05.
* Two separate models were constructed for each outcome. The GVHD
prophylaxis regimen was entered into all multivariate models as a
confounder variable for adjustment only (multivariate results are not shown
for this variable).
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post-transplant interventions in prospective clinical trials
and possibly in standard clinical practice.
In our study, more than half of the relapsing patients
experienced disease relapse by day 100. The outcome of
relapsing patients was poor, with a median survival of 4.9
months from the time of relapse and a 3-year survival of
18%. Similar outcomes have been previously reported
[8,9,31-33], highlighting the importance of identifying pa-
tients at high risk for relapse at a very early time point after
transplant.
The associations of day-30 chimerism with relapse, RFS,
and OS were signiﬁcant, continuous, and clinically mean-
ingful. In assessing the relative goodness of ﬁt of the models,we found an advantage toTcell chimerism in prediction of all
outcomes. These ﬁndings strengthen the rationale for the use
of both WB and T cell chimerism early after RIC HSCT.
The predictive value of peripheral blood chimerism
testing after RIC HSCT was previously examined. It was
commonly, but not universally, observed that low T cell
chimerism predicts graft rejection, whereas high T cell
chimerism is associated with GVHD [20-22,34-36]. For
relapse and survival outcomes, previous studies have
demonstrated conﬂicting results. Early studies of RIC HSCT
noted that complete T cell donor chimerism seemed to pre-
cede malignant disease responses [21,37]. These ﬁndings
were not conﬁrmed by other studies, possibly because of
heterogeneity in conditioning regimens and inclusion of T
celledepleting antibodies in some studies [19,20,38,39].
Several studies attempted to use CD34 cellespeciﬁc chime-
rism and found that either a low level or a decline in the
CD34 cell chimerism level predicted relapse; however, this
test is not always feasible early after transplant and is likely
limited to patients with acute leukemia and myelodysplastic
syndromes [14,40].
These conﬂicting results regarding the predictive value of
chimerism testing possibly reﬂect the heterogeneity in
studied populations in previous studies, inclusion of multiple
conditioning regimens and graft sources, and inconsistent
timing of testing. In our study, we aimed to overcome some
of these barriers by studying patients who received a uni-
form, widely used conditioning regimen and received pe-
ripheral blood stem cells only. We also focused on a single
early time point (day 30), which we believe is the most
relevant after RIC HSCT because of the high incidence of early
relapse. Another major difference is that most previous
studies focused on achievement of complete donor chime-
rism using a historical threshold of 95% (or similar), whereas
we handled chimerism levels as continuous variables. The
rationale for our approach is that the analytic sensitivity of
this assay has improved because of advances in technology
and standardization. The EuroChimerism Consortium re-
ported a detection limit of .8% to 1.6% and conﬁdence in-
tervals of 1.6% to 1.8% for donor chimerism levels > 94% [41].
Our lab’s internal validation is in line with these results,
which allows us to take advantage of this molecular test with
high precision. Our results show that the predictive value of
both WB and T cell chimerism levels is sustained across a
wide range of values and not just at the historical threshold
of 95%.
The ﬁndings of this study can be immediately applied.
The primary advantage of chimerism measurement is that it
can be done in all patients even in the absence of disease-
speciﬁc information. This stands in contrast to other types
of minimal residual disease (MRD) testing such as muti-
parameter ﬂow cytometry or quantitative PCR, which are
limited to patients with a known immunophenotype or
molecular abnormality [42]. These novel MRD assays are
emerging as useful prognostic markers before transplant
[43,44], but their clinical utility in post-transplant moni-
toring has been questioned, because the detection of
leukemic cells early after transplant is not always predictive
of relapse [45]. After RIC in particular, positive MRD is
common, and residual malignant cells can still be eradicated
by the potent graft-versus-tumor response. A strategy that
combines chimerism testing with other MRD methods can
be envisioned to further increase the sensitivity of MRD
detection and ensure that all patients beneﬁt from early
prognostication regardless of disease.
Figure 2. Univariate associations of disease relapse with day-30 donor chimerism levels. Cumulative incidence plots of disease relapse are shown, starting from the
time of day-30 chimerism testing (deﬁned here as “0” for a landmark analysis). Comparative plots for groups of patients who had higher or lower than median
chimerism levels are presented for WB (A) and T cell chimerism (C). Hazard ratios and P values represent a univariate cumulative incidence analysis. All possible
cutoffs for WB (B) and T cell chimerism (D) were examined and plotted against the cutoffs, showing signiﬁcant correlations at multiple cutoffs. The plot lines
represent a moving 3-point average.
R. Reshef et al. / Biol Blood Marrow Transplant 20 (2014) 1758e17661764We did not identify any correlation between day-30
chimerism and GVHD. Previous studies have shown con-
ﬂicting results on this association [19,20,22,37]. In our
cohort, acute GVHDwas often delayed, with amedian time to
onset of 4.7 months post-transplant, which could explain
why early chimerism measurement on day 30 failed to
predict this outcome. It is possible that chimerism mea-
surements at later time points, or trends between serial
measurements, have a better predictive value for this
outcome.Figure 3. Pearson correlation between day-30 WB and T cell chimerism levels.
Day-30 WB and T cell chimerism levels are plotted against each other (n ¼
103), demonstrating a signiﬁcant correlation by Pearson.In our study, the early (day-30) achievement of high
chimerism levels was strongly associated with a lympho-
penic state before transplant. Lymphopenic individuals may
have better homeostatic expansion of donor T cells [46], and
retrospective studies have noted that a higher number of
antitumor therapies before transplant predicted early com-
plete donor chimerism, which can be mechanistically linked
to lymphopenia [19,20,22]. This was also shown prospec-
tively in a study inwhich accelerated donor engraftment was
achieved with lymphodepleting chemotherapy before RIC
HSCT for lymphoma [47]. Our results demonstrate that lower
pretransplant lymphocyte counts are associated with faster
engraftment in any disease, not just in lymphomas, sug-
gesting that aggressive lymphodepletion before transplant
can be used broadly to accelerate donor cell engraftment.
Ultimately, randomized studies will be required to demon-
strate the effect of lymphodepletion on transplant outcomes.
Certain limitations to our study should be noted. For
uniformity, we focused on a single RIC regimen (ﬂudarabine/
busulfan), which is the most commonly used RIC regimen
according to 2011 Center for International Blood andMarrow
Transplant Research data (Marcelo Pasquini and Brent Logan,
personal communications). Whether the kinetics of
engraftment differs among RIC regimens is unknown, but it
has been suggested that melphalan-based regimens achieve
complete T cell chimerism more rapidly, implying the pre-
dictive value of chimerism should be validated for other
regimens [19]. Our study also analyzed the outcomes of a
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acteristics (eg, disease type, cytogenetic risk). The DRI that
was recently validated in more than 13,000 patients was
used to adjust our analyses to overcome this barrier [23]. In
addition, we analyzed broad disease categories (myeloid
versus lymphoid, acute leukemia versus others) and found
no signiﬁcant impact on any outcomes or interactions with
any of the important covariates. However, the small number
of patients in some of the disease categories precluded
meaningful disease-speciﬁc analyses.
The clinical utility of any prognostic biomarker is limited
if not tied with a strategy that prevents overt relapse. It is
known that reduction of immunosuppression and DLI can
convert mixed chimerism to complete donor chimerism and
even eliminate measurable residual disease [45,48-50].
Whether this can be safely, rapidly, and meaningfully ach-
ieved without excessive toxicity as early as 30 days after
HSCT is unknown. More recently, maintenance regimens
such as methyltransferase inhibitors and targeted therapies
(eg, FMS-like tyrosine kinase receptor-3 [FLT3] inhibitors)
have entered clinical trials in the early post-transplant
setting [51-54], but, similarly, whether these interventions
can be safely initiated very early after transplant remains to
be determined. The ﬁndings of our study suggest that low
WB or T cell chimerism levels on day 30 after RIC HSCT
indicate a higher risk for relapse independent of any other
indicators. This may help inform patient selection for ap-
proaches such as enhanced tapering or withdrawal of
immunosuppression, preemptive DLI, or experimental ther-
apy. The safety and efﬁcacy of these approaches will need to
be examined in prospective clinical trials.
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